Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8118941 | 0.85 | ALDH1A1 (0.45) | ALDH1A1CASP1TSHRCYP3A4PDE10A | |
| SCHEMBL26923043 | 0.81 | ALDH1A1 (0.45) | ALDH1A1PLA2G7CASP1TSHRCYP3A4 | |
| SCHEMBL30714540 | 0.80 | AXL (0.56) | ALDH1A1PLA2G7CYP3A4ABL1MAPT | |
| SCHEMBL1439800 | 0.80 | AXL (0.56) | ALDH1A1PLA2G7CYP3A4ABL1MAPT | |
| SCHEMBL7088870 | 0.80 | EGFR (0.41) | ALDH1A1CASP1TSHRCYP3A4EGFR | |
| SCHEMBL25593208 | 0.79 | PLA2G7 (0.47) | ALDH1A1PLA2G7CASP1TSHRCYP3A4 | |
| SCHEMBL30714465 | 0.79 | ABL1 (0.41) | ALDH1A1PLA2G7CASP1TSHRCYP3A4 | |
| SCHEMBL26923550 | 0.79 | ABL1 (0.41) | ALDH1A1PLA2G7CASP1TSHRCYP3A4 | |
| SCHEMBL3783964 | 0.77 | ALDH1A1 (0.54) | ALDH1A1PLA2G7CASP1TSHRCYP3A4 | |
| SCHEMBL10305281 | 0.77 | ABL1 (0.49) | ABL1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1626532-A | Amide compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | CN | disclosed |
| US-20040266774-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| CN-1170826-C | Amide compound | ����ҩƷ��ҵ��ʽ���� | 2004-10-13 | — | — | CN | disclosed |
| US-6770667-B1 | N-((IMIDAZOLYL)-PHENYL)-FLUORENE-1-CARBOXAMIDE DERIVATIVES; 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONISTS; PSYCHOLOGICAL, NERVOUS SYSTEM, EATING, BRAIN AND SLEEP DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| CN-1376153-A | Amide compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-23 | — | — | CN | disclosed |
| EP-1216240-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001025229-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | ALDH1A1 2908/4885PLA2G7 320/4885CASP1 514/4885 |
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | ALDH1A1 2482/4885PLA2G7 3972/4885CASP1 2930/4885 |
| US-20040266774-A1 | Amide compounds | TPH1, HTR1A, HTR5A | ALDH1A1 386/4885PLA2G7 1840/4885CASP1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.